The drugmaker announced topline results from its phase 1 trial of its Amycretin pill on March 7, and following the announcement, Novo Nordisk shares jumped 7.5%, according to The Wall Street Journal.
In the trial, patients taking Amycretin lost about 13% of their body weight in 12 weeks — more than double the weight lost during the same time period with Wegovy, which was about 6%.
The pill is taken once daily and is slated to head into phase 2 trials later this year, the Journal reported. However, Barclays analysts wrote in a note that Novo Nordisk has “not ruled out going [straight] into Phase 3 development,” with the drug.
In addition to the pill, Novo Nordisk also noted it has about 10 other obesity treatments currently in development.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
